Martingale Asset Management L P Has $529,000 Holdings in Hologic, Inc. (HOLX)

Share on StockTwits

Martingale Asset Management L P lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 81.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,856 shares of the medical equipment provider’s stock after selling 55,371 shares during the period. Martingale Asset Management L P’s holdings in Hologic were worth $529,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HOLX. Oregon Public Employees Retirement Fund grew its position in shares of Hologic by 3,960.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,222,766 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 1,192,649 shares during the last quarter. Capital International Investors bought a new stake in shares of Hologic in the 3rd quarter valued at about $48,560,000. The Manufacturers Life Insurance Company grew its position in shares of Hologic by 135.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,958,778 shares of the medical equipment provider’s stock valued at $80,270,000 after buying an additional 1,128,328 shares during the last quarter. Man Group plc grew its position in shares of Hologic by 453.6% in the 3rd quarter. Man Group plc now owns 1,131,685 shares of the medical equipment provider’s stock valued at $46,376,000 after buying an additional 927,244 shares during the last quarter. Finally, Capital World Investors grew its position in shares of Hologic by 2.5% in the 3rd quarter. Capital World Investors now owns 27,808,896 shares of the medical equipment provider’s stock valued at $1,139,609,000 after buying an additional 671,524 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Shares of HOLX opened at $47.36 on Friday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.30 and a quick ratio of 0.91. The company has a market cap of $13.74 billion, a P/E ratio of 21.24, a price-to-earnings-growth ratio of 2.21 and a beta of 0.75. Hologic, Inc. has a 12 month low of $35.10 and a 12 month high of $48.11.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, January 30th. The medical equipment provider reported $0.58 EPS for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.01. The company had revenue of $830.70 million during the quarter, compared to the consensus estimate of $823.22 million. Hologic had a positive return on equity of 25.59% and a negative net margin of 12.88%. Hologic’s revenue was up 5.0% on a year-over-year basis. During the same period last year, the business posted $0.55 earnings per share. On average, equities research analysts predict that Hologic, Inc. will post 2.41 EPS for the current year.

In other Hologic news, insider Peter J. Valenti III sold 4,242 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $47.38, for a total value of $200,985.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin Jordan Cohn sold 6,830 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $46.70, for a total value of $318,961.00. Following the completion of the sale, the insider now directly owns 22,002 shares of the company’s stock, valued at $1,027,493.40. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.

A number of equities research analysts have commented on the company. TheStreet upgraded Hologic from a “c” rating to a “b” rating in a research report on Monday, March 4th. Zacks Investment Research upgraded Hologic from a “hold” rating to a “buy” rating and set a $53.00 price target on the stock in a research report on Tuesday, March 5th. BidaskClub upgraded Hologic from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 15th. ValuEngine upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Friday, February 15th. Finally, BTIG Research reiterated a “buy” rating and issued a $50.00 price target on shares of Hologic in a research report on Thursday, January 31st. One research analyst has rated the stock with a sell rating, nine have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $44.52.

TRADEMARK VIOLATION NOTICE: This piece was posted by Week Herald and is owned by of Week Herald. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://weekherald.com/2019/03/15/martingale-asset-management-l-p-has-529000-holdings-in-hologic-inc-holx.html.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Read More: What factors cause inflation to rise?

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.